Journalists Assess Health Impacts of Trump’s Megabill, Who Will Feel Them, and When

KFF Health News chief Washington correspondent Julie Rovner discussed how cuts to Medicaid in President Donald Trump’s megabill will affect Americans’ access to health care on NPR’s “Up First,” CNN’s “CNN This Morning” and WNYC’s “The Brian Lehrer Show” on July 2. Rovner also discussed U.S. domestic and global vaccine policy on WAMU’s “1A” on July…

Read More

Friday Links

Trends in cost-related non-adherence.Optum Rx reduces reauthorization requirements.Changes in insulin out-of-pocket costs over time.AI and billable hours.Value in Health to include ‘Plan Language Summaries’

Read More

With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short

Dizal Pharmaceutical’s Zegfrovy is now FDA approved for treating non-small cell lung cancer driven by a particular rare genetic signature. Johnson & Johnson drug Rybrevant already addresses this genetic signature as an earlier line of therapy, but Dizal executives contend their drug offers the potential for better safety and efficacy. The post With FDA Nod…

Read More

States Brace for Reversal of Obamacare Coverage Gains Under Trump’s Budget Bill

Shorter enrollment periods. More paperwork. Higher premiums. The sweeping tax and spending bill pushed by President Donald Trump includes provisions that would not only reshape people’s experience with the Affordable Care Act but, according to some policy analysts, also sharply undermine the gains in health insurance coverage associated with it. The moves affect consumers and…

Read More